PERI-OPERATIVE CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER: OVERVIEW AND A RATIONALE FOR THE NEED TO SEEK ALTERNATIVE TREATMENT: MAGNOLIA CLINICAL TRIAL

The paper gives an overview of peri-operative chemotherapy in patients with muscle-invasive bladder cancer (MIBC) as insufficient option, demonstrates a clinical need for the development of more efficacious and safe treatment and introduces a MAGNOLIA study proposed by the European Association of Urology Research Fund in a concept of MIBC immunotherapy. The MAGNOLIA trial conducted in 56 research centers of 10 countries assesses whether adjuvant immunotherapy with recMAGE-A3+AS15 vaccine is safe and effective and improves outcome of patients with MAGE-A3 positive MIBC after cystectomy. 60 of 273 patients have been enrolled. The trial has to be continued to elaborate a general peri-operative treatment strategy for MIBC.

1. Shariat S. F., Karakiewicz P. I., Palapattu G. S. et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176 (6 Pt 1):2414–22; discussion. 2422. http://www.ncbi.nlm.nih.gov/pubmed/17085118

2. Hautmann R. E., Gschwend J. E., de Petriconi R. C. et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006;176 (2):486–92; discussion 491–2.

3. http://www.ncbi.nlm.nih.gov/pubmed/16813874

4. Sternberg C. N., Vogelzang N. J. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 2003;46 (Suppl): 105–15.

5. http://www.ncbi.nlm.nih.gov/pubmed/12850531

6. Bellmunt J., Petrylak D. P. New therapeutic challenges in advanced bladder cancer. Semin Oncol 2012;39(5):598–607. http://www.ncbi.nlm.nih.gov/pubmed/23040256

7. Sternberg C. N., de Mulder P., Schornagel J. H. et al. EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M–VAC chemotherapy and G-CSF versus classic M–VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42 (1):50–4.

8. http://www.ncbi.nlm.nih.gov/pubmed/16330205

9. Sternberg C. N., Bellmunt J., Sonpavde G. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 2013;63 (1):58–66. http://www.ncbi.nlm.nih.gov/pubmed/22917984

10. Gore J. L., Lai J., Setodji C. M. et al. Urologic Diseases in America Project. Mortality increases when radical cystectomy isdelayed more than 12 weeks: resultsfrom a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 2009;115 (5):988–96.

11. http://www.ncbi.nlm.nih.gov/pubmed/19142878

12. Burger M., Mulders P., Witjes W. Use of neoadjuvantchemotherapy for muscleinvasive bladder cancer islowamong major European centres: results of a feasibility questionnaire. Eur Urol 2012;61(5):1070–1.

13. http://www.ncbi.nlm.nih.gov/pubmed/22336379

14. Niegisch G., Lorch A., Droller M. J. et al. NeoadjuvantChemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit? Eur Urol 2013;64 (3):355–7.

15. http://www.ncbi.nlm.nih.gov/pubmed/23773558

16. Gure A. O., Chua R., Williamson B. et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. J Clin Oncol 2005; 11(22):8055–62.

17. http://www.ncbi.nlm.nih.gov/pubmed/16299236